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EIGHTEEN YEARS OF PHARMACOGENETICS  
 Pharmacogenetics and personalized prescription have long and overlapping histories but they were 
probably born with the DNA microarray technology which allows parallel genetic testing.1 In 1997, 
Science defined “personalized prescription” as “tailoring drugs to a patient’s genetic makeup” and 
predicted that personalized prescription would “soon” reach clinical practice. The end of the race for the 
Human Genome in 2000 led to further hype. The most widely circulated US news magazine, Time, 
predicted that the generalized use of personalized prescription would begin in 2015, while JAMA 
predicted 2020. Now that it’s 2015, are we any closer to using pharmacogenetic testing to guide our 
pharmacological treatments? The answer is obviously, “No”. “No” both in child psychiatry and medicine 
in general.  
 How is it possible that personalized prescription has not reached adulthood in 2015 following 
those rosy predictions? The answer lies in two facts: 1) the process of implementing pharmacogenetic 
testing under the auspices of the Food and Drug Administration (FDA) was flawed, and 2) personalizing 
prescription is even more complex than pharmacogenetic testing, as the story of atomoxetine 
demonstrates.  
THE FDA AND PHARMACOGENETICS 
In the 1990s, the FDA implemented guidelines to encourage the introduction of pharmacogenetic 
testing in the clinical environment and defined the cytochrome P450 2D6 (CYP2D6) as a “valid 
biomarker.” The pharmaceutical companies felt threatened; new drugs would be subjected to the 
complications of pharmacogenetic testing and/or potentially smaller markets. CYP2D6 is the main 
metabolic enzyme for many psychiatric drugs but, due to the unpredictable twists of evolution, it is absent 
in 7% of Caucasians. They have two non-functional CYP2D6 alleles and are called poor metabolizers 
(PMs). On the other hand, approximately 1.5% of US Caucasians and African-Americans have 3 or more 
active alleles, and produce more than normal quantities of CYP2D6 in their livers. They are called 
ultrarapid metabolizers (UMs). To avoid problems, the pharmaceutical companies decided to eliminate 
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from their pipelines drugs heavily dependent on CYP2D6 for their metabolism; atomoxetine was one of 
the last ones marketed. Its manufacturer had to meet the FDA guidelines and demonstrate that 
atomoxetine was safe for CYP2D6 PMs.  
COMPLEXITIES OF PERSONALIZED PRESCRIPTION AND PHARMACOGENETICS 
FDA guidelines do not sufficiently account for the complexity of the clinical environment, as PM 
status can be explained by different mechanisms. Obviously, genetics may cause CYP2D6 PM status. 
Secondly, clinicians can produce PM status by prescribing powerful CYP2D6 inhibitors, such as 
paroxetine or fluoxetine, which can cause patients with normal CYP2D6 activity, called extensive 
metabolizers (EMs), to behave as if they have no CYP2D6 activity. This exemplifies CYP2D6 PM status 
explained by environmental factors. Lastly, for some CYP2D6 drugs partly eliminated by the kidney, 
such as risperidone, renal insufficiency can account for individuals who look like PMs; in this case a 
personal factor has produced a CYP2D6 PM status. 
Therefore, personalized prescription should include genetic as well as environmental (e.g., co-
medications, herbal medicines, smoking, foods, beverages) and personal (e.g., age, gender, ethnicity, 
illness) variables.2 To further complicate things, personalized prescription can be expressed as 
personalizing dosing and/or drug selection, and should consider pharmacokinetic and pharmacodynamic 
mechanisms which influence both the safety and efficacy of drugs.  In the case of atomoxetine, one of 
these pieces in the complex puzzle of personalized prescribing was ignored, namely, the width of its 
therapeutic index (or window).3  
 The best way of implementing personalized dosing2 is by combining pharmacogenetics with blood 
levels, which pharmacologists call therapeutic drug monitoring (TDM). Unfortunately for atomoxetine, its 
data is hampered since 1) all the related pharmacogenetic studies focused on CYP2D6 PMs and safety 
during the randomized clinical trials (RCTs), as required by the FDA; and 2) the published TDM data 
focuses on peak concentrations, which are harder to interpret than the steady-state trough levels studied by 
the traditional TDM studies in the clinical environment.   
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ATOMOXETINE AND CYP2D6 PMs  
In pharmacokinetic studies, at steady state, after twice-daily dosing, the mean steady-state plasma 
concentrations were approximately 10-fold higher in CYP2D6 PMs than in CYP2D6 EMs. However, 
these pharmacokinetic differences had no relevance to adverse drug reactions (ADRs) during the RCTs. 
The most comprehensive ADR report4 compared 87 CYP2D6 PMs and 1239 CYP2D6 EMs. Despite a 
lower mean dose in PMs, they demonstrated, when compared with EMs, marginally better efficacy in 
response rate (85% vs. 82%, p=0.56, odds ratio, OR calculated with article data by this author=1.2, 95% 
confidence interval, CI, 0.79-2.1) and comparable ADR profiles with a difference in discontinuation due 
to ADRs of 6% vs. 2% (OR=2.5, 1.1-5.6), which did not reach significance (p=0.08).  
Atomoxetine was marketed and the US prescribing information (or package insert) recommends 
lower doses for CYP2D6 PMs or those taking CYP2D6 inhibitors, but it makes no comment on the need 
for CYP2D6 genotyping before prescribing atomoxetine. Thus, child psychiatrists do not need to worry 
about CYP2D6 genotyping when prescribing atomoxetine. 
ATOMOXETINE AND CYP2D6 UMs    
 Atomoxetine follows linear kinetics. This means that the relationship between concentration doses 
is stable and very predictable. The pharmaceutical company should have focused not on atomoxetine 
ADRs in CYP2D6 PMs, but on the lack of efficacy in CYP2D6 UMs. As CYP2D6 PMs have a 10-fold 
increase in atomoxetine levels with no relevant increase in ADRs, this proves that atomoxetine is a very 
safe drug with a wide therapeutic index. Prior pharmacological experience indicates that in drugs with a 
wide therapeutic index, one needs to focus on UMs, who may not have sufficient drug levels at the usual 
recommended dosages.3  
Table 1 describes the response rate at the endpoint of the acute treatment phase5 and uses these 
response rates to make predictions. To increase the response rate of EMs in the acute phase from the 60% 
obtained to the 80% seen in CYP2D6 PMs, one needs to get the same atomoxetine levels in CYP2D6 
EMs as in PMs. As atomoxetine follows linear kinetics, one would have to increase the EM dose 10-fold 
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to get approximately the same mean plasma concentration as the PMs in the RCTs. Table 1 indicates that 
up to 20% of CYP2D6 EMs were underdosed in the RCTs, which may have contributed to a 9% increase 
in dropouts due to lack of efficacy in CYP2D6 EMs.  
In the RCTs, CYP2D6 UMs were included in the CYP2D6 EM group and probably were heavily 
overrepresented in the group lacking efficacy. Assuming that atomoxetine follows linear kinetics and that, 
as in other CYP2D6 drugs, UMs had an increase in metabolism by at least a factor of 2 when compared 
with EMs, one needs to conclude that, during the RCTs, CYP2D6 UMs probably had less than half the 
atomoxetine levels as EMs, and approximately 20 times less than CYP2D6 PMs. If this is correct, UM 
doses 20 times higher than used in the RCTs would provide the 80% response rate seen in CYP2D6 PMs.   
New studies using CYP2D6 genotyping and TDM are needed to establish whether or not higher 
atomoxetine doses are required for CYP2D6 UMs (1.5% in US Caucasians and 2.0% in African-
Americans) and possibly in CYP2D6 EMs with ≥2 more active alleles (respectively, 36.4% and 18.3%) 
who may not respond to recommended doses. Unfortunately, the independent investigators testing this 
hypothesis would have to start from scratch, as CYP2D6 UM response information is absent and 
atomoxetine TDM data is limited. The company completed a study of two-times higher doses of non-
responders that was negative, but was not guided by TDM or CYP2D6 genotyping. The author proposes 
that after CYP2D6 genotyping, those subjects with ≥2 active alleles, which in total account for 
approximately one-third of US individuals, can be treated with much higher atomoxetine doses than those 
recommended in the package insert, as long as atomoxetine TDM demonstrates safe steady-state trough 
concentrations similar to those seen in CYP2D6 PMs with recommended doses. 
In summary, clinicians may need to be aware that normal atomoxetine doses may not be enough  
for CYP2D6 UMs3 and possibly for CYP2D6 EMs ≥2 active alleles. As a matter of fact, in 2011 The 
Royal Dutch Association for the Advancement of Pharmacy’s CYP genotyping guidelines concurred that 
dosing atomoxetine in CYP2D6 UMs is problematic and recommended that clinicians “be alert to reduced 
efficacy or select alternative drugs.” Researchers interested in studying patients who do not respond to 
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atomoxetine have the challenge of building a new database by combining the concepts of CYP2D6 
genotyping, atomoxetine TDM and wide therapeutic index. 
THE DIFICULTIES OF IMPLEMENTING PERSONALIZED MEDICINE 
Atomoxetine exemplifies why personalized medicine and pharmacogenetic testing are not widely 
used in 2015 by child psychiatrists or physicians in general. Personalizing prescription is a complex 
pharmacological puzzle that 1) can focus on drug dosing or drug selection; 2) requires combining genetics, 
environmental and personal variables; and 3) necessitates understanding pharmacokinetic and 
pharmacodynamic mechanisms in order to predict efficacy and safety. If one focuses on dosing, one also 
needs to consider the drug’s therapeutic index. As a matter of fact, as each patient is a “unique individual” 
with different drug responses governed by pharmacological laws, each drug may also be a “different 
individual” governed by its specific pharmacological mechanisms.    
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Table 1.Comparing atomoxetine response ratea of CYP2D6 PMs to EMs      
     RCT dose              Predictions if dose is 10 times higher  
     PMs EMs Difference EMs       
N     30 559     
Response rate     80% 60% 20%b  80% 
Dropouts due to lack of efficacy 18% 27% -9%c  18%      
CI: 95% confidence interval; EM: extensive metabolizer; PM: poor metabolizer; OR: odds ratio; RCT: randomized clinical 
trial.  
aAt the endpoint of the acute treatment phase. 
bThis difference was described as significant (p=0.033).5 The author estimated an OR comparing PMs vs. EMs of 2.7, CI, 1.3-
5.9. 
cThis difference was described as significant (p=0.004).5 The OR comparing PMs vs. EMs was 0.57, CI, 0.40-0.79. 
